1469-0691/asset/bannerforeground.jpg?v=1&s=d64312ac8b913a4f04c6e0a755daba751d8d8d8d)
Extended-spectrum β-lactamases in ambulatory care: a clinical perspective
Article first published online: 11 DEC 2007
DOI: 10.1111/j.1469-0691.2007.01866.x
© 2008 The Authors
Issue
Clinical Microbiology and Infection
Special Issue: ESBLs, Forever?
Volume 14, Issue Supplement s1, pages 104–110, January 2008
Additional Information
How to Cite
Rodríguez-Baño, J. and Navarro, M. D. (2008), Extended-spectrum β-lactamases in ambulatory care: a clinical perspective. Clinical Microbiology and Infection, 14: 104–110. doi: 10.1111/j.1469-0691.2007.01866.x
Publication History
- Issue published online: 11 DEC 2007
- Article first published online: 11 DEC 2007
Errata concerning Volume 14, Supplement 1, January 2008
Vol. 14, Issue 3, 293, Article first published online: 31 JAN 2008
- Abstract
- Article
- References
- Cited By
Keywords:
- ambulatory care;
- antimicrobial resistance;
- bacteraemia;
- β-lactamases;
- Escherichia coli;
- review;
- urinary tract infections
Abstract
Extended-spectrum β-lactamase (ESBL)-producing organisms are emerging as a cause of infection in outpatients in many areas of the world. Most of these involve urinary tract infections caused by Escherichia coli harbouring CTX-M types of ESBLs. Risk-factors for such infections include older age and previous use of quinolones and cephalosporins. Oral alternatives for such infections are limited. These organisms may also cause some community-acquired life-threatening infections, such as bacteraemic urinary tract or intra-abdominal infections. Patients with these infections are at increased probability of receiving inappropriate empirical treatment. More studies addressing the risk-factors and therapeutic options for these infections are needed.